The ‘Stupp trial’ and the RTOG0525 trial have provided definitive evidence for the prognostic significance of MGMT gene promoter methylation in patients newly diagnosed with glioblastoma multiforme (GBM). This evidence concerns the gene MGMT and glioblastoma.